Compare Cassava Sciences Inc (FLNA) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Moody's Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Moody's Corporation trades at $464 (market cap $79.44B). The key difference: Moody's Corporation is far larger — about 2016.2× Cassava Sciences Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Moody's Corporation for 132 Days on average.
| FLNA | MCO | |
|---|---|---|
Market Cap | $39.40M | $79.44B |
Volume | 759,018 | 526,684 |
Sector | Health | Financials |
52-Week High | $4.64 | $539.61 |
52-Week Low | $0.68 | $412.23 |
Typical Hold Time | 37 Days | 132 Days |
Enterprise Value | -$43.28M | $85.46B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
Moody's Corporation (MCO) trades at $462.10, up 2.77% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals with 34.25% net margins and 80.15% ROE, though technical indicators signal near-term bearish pressure. Recent strategic moves include expanding Asia-Pacific presence through a PhilRatings stake and new credit risk product launches.
Outlook remains positive given consistent earnings beats and analyst consensus target of $536.40 (16% upside). Key risks include high valuation multiples (P/E 29.1) and potential macroeconomic sensitivity affecting credit rating demand. Institutional sentiment leans bullish with 56% buy ratings supporting long-term growth thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
